Near-death experiences (NDEs) might be more common than most would think, according to a new study by the International Association for Near-Death Studies. 

The study reveals that 23 percent of American adults report having had a near-death experience, after which they returned to normal human existence. The study also reveals that 35 percent of the individuals queried about such experiences who have not had an NDE themselves said they know someone who has. 

“In an NDE, usually during a close brush with death, a person has a vivid, emotionally intense experience of lucidly perceiving the material world from a position outside the physical body and/or perceiving and interacting with beings and environments not of the material world,” said Janet Riley, executive director of the International Association for Near-Death Studies, in an email to The Debrief. “Afterward, experiencers are usually profoundly changed.”

The survey, conducted in March 2026 by Centiment and involving 2,100 Americans, looked more deeply at the effects of these experiences. Among those who reported having an NDE, 51 percent said the experience gave them a deeper meaning and appreciation for life, while 37.6 percent said they felt more connected to a “spiritual realm.”

Overall, thirty-one percent said the experience changed their life priorities; 30 percent said they were less afraid of death than before; 30 percent reported greater empathy for others; and 26 percent said they had become more generous and socially minded.

Among respondents who knew a friend or family member who had experienced an NDE, 44 percent said they became more curious about the afterlife, while 40 percent reported a stronger belief in life after death.

“This remarkable data tells us three important things: NDEs may be more common than we realized; people who have NDEs or hear about them are positively impacted, and the majority of Americans believe evidence exists to support the phenomena,” Riley said in a statement. “The survey also makes clear the importance of normalizing conversations about life, death, and what comes after. Those who have had NDEs or who research them may be some of the best teachers.”

What about those who have never had an NDE?

Additionally, the survey revealed that 27.3 percent of participants who had never experienced an NDE themselves found the evidence significant enough to change their minds, while 31.3 percent said it at least provided reliable evidence for some type of phenomenon.

The smallest category of responding participants, at 15 percent, said there was limited evidence, while 24 percent said there was insufficient evidence.

Nearly four out of five respondents (79.8 percent) said there is either some value (36.7 percent) or major value (41.1 percent) in studying near-death experiences.

A Paradigm Shift? 

Culturally, perceptions about NDEs and related subjects may be changing, and mainstream attitudes may be evolving. Even in the world of pop culture, celebrity gossip columnist Perez Hilton (Mario Armando Lavandeira Jr.), known for his often controversial commentary, has spoken publicly about a near-death experience after taking flu medication without food, which led to a stomach ulcer, perforation, and severe sepsis. He ultimately spent 21 days in the hospital.

After the experience, Hilton said he was appalled by his “selfish behavior” and offered apologies, explaining that after finding God, he came to regret the fact that, as he put it, “I didn’t care who I hurt.”

The International Association for Near-Death Studies survey also asked participants whether death frightened them. Twenty-five percent said the idea of dying scared them “a little,” while 14.8 percent said it scared them “a great deal.” However, 31 percent said they felt confident that they would be in a better place after death, while only 6.2 percent worried they would be in a worse place. Another 25 percent said they had “made peace with death.”

“We were founded as a research organization, and no survey like this had occurred recently,” Riley explained. “Given the strong interest in near-death experiences, we thought a survey would be timely.”

“We also felt that communicating the results could help normalize conversations about the phenomenon, which some people are reluctant to share because they fear not being taken seriously,” Riley added.

With this high level of confidence in life after death, such beliefs may continue to spread further into the mainstream, influencing everyday life and shaping how people view themselves and the world around them.

“We also know from NDE research that those who have had the experiences feel a deep connection to others, feel more loving and spiritual, and often feel more altruistic and generous,” Riley says. “We believe connection, love, altruism, and generosity have the potential to make the world a better place.”

Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com. To contact Chrissy with a story, please email chrissy @ thedebrief.org.

In the relentless quest to understand and conquer cancer, researchers have honed in on a new molecular frontier—Coenzyme Q10 (CoQ10) oxidoreductases and their pivotal role in ferroptosis, a unique form of programmed cell death distinguished by iron-dependent lipid peroxidation. The insight uncovered by Lee, Yoo, Kim, and colleagues, published in the June 2026 issue of Experimental & Molecular Medicine, unveils a complex interplay between redox homeostasis, cancer cell survival, and ferroptotic susceptibility, promising innovative therapeutic avenues that could revolutionize oncology.

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026

According to Benjamin Franklin two things are inevitable: death and taxes. Research shows that human lifespan has a natural limitation, due to the decline of physiological resilience. Contrast the desire of the evil elites to overcome death using barbaric practices with the immortality offered by Jesus Christ.

The Curse resulted in decay, disease, and death affecting the entire creation, meaning the whole universe. The effects are seen in the cosmos and in living organisms. However a future restoration of creation is promised by God, reversing the effects of the Curse.

God cursed the creation which led to the emergence of diseases like cancer. But He also provided treatments for some of those diseases. Euphorbia peplus is such a plant, which is traditionally used to treat skin cancers. It is one natural remedy available from the weeds of the cursed creation.

Excess deaths linked to Covid vaccines in Australia, alarming death and disease surges identified in Japan, and humanitarian crises in Gaza are in the news. But there is hope. Death is the last enemy which will be conquered by Jesus Christ.

Jesus Christ's teachings on love radically contrast Old Testament views, urging compassion towards enemies. His message emphasizes mourning rather than celebrating death, highlighting that all humans, regardless of their actions, deserve empathy and are made in God's image.

Heart failure following myocardial infarction has long presented a formidable challenge to clinicians worldwide. Despite advances in acute cardiac care, the progression from initial infarction to chronic heart dysfunction remains frequent and devastating. Recent groundbreaking research from The University of Osaka, Japan, has unveiled a promising multipronged therapeutic strategy that leverages the power of mRNA technology to repair the heart after injury. This innovative approach, detailed in the journal Small Science, introduces a sophisticated delivery system based on polyplex nanomicelles to simultaneously administer multiple therapeutic mRNAs directly into damaged heart tissue.

Myocardial infarction precipitates a complex pathological cascade characterized by inflammation, cardiomyocyte death, fibrotic scar formation, and impaired vascularization. These processes collectively undermine cardiac contractility and structural integrity, eventually leading to heart failure. Traditional therapeutic modalities have largely targeted isolated components of this cascade, often rendering limited efficacy due to the multifaceted nature of post-infarction remodeling. The challenge lies in addressing the intricate interplay between cell death, extracellular matrix remodeling, and neovascularization simultaneously, a feat that the current study aims to achieve.

The research team employed a nanotechnology-based delivery vehicle termed polyplex nanomicelles—engineered polymeric carriers designed to protect and transport mRNA molecules efficiently while facilitating their targeted uptake by cardiac cells. By harnessing these nanomicelles, the scientists could convey a cocktail of five distinct mRNAs encoding proteins critical to various repair mechanisms. This multi-mRNA cargo was administered in a controlled manner into the myocardium of a murine heart failure model induced by ischemic injury.

A key advantage of this polyplex nanomicelle system is its ability to overcome the inherent instability and rapid degradation of naked mRNA in vivo. The nanomicelles form condensed complexes with mRNA strands, shielding them from enzymatic breakdown while ensuring sustained release and translation into functional proteins within the cardiac microenvironment. This delivery technology not only amplifies therapeutic efficacy but also minimizes off-target effects and immune activation that typically complicate gene therapy approaches.

The functional proteins encoded by the co-delivered mRNAs orchestrate complementary reparative actions in the infarcted myocardium. They promote angiogenesis, the process of new blood vessel formation essential for supplying oxygen and nutrients to regenerating tissue. Simultaneously, these factors inhibit fibrotic scar deposition by modulating fibroblast activity, thus preserving myocardial compliance and contractile function. Additionally, by fostering cardiomyocyte survival and proliferation, they directly counteract cell loss and support myocardial regeneration.

Experimental results from the murine heart failure models were striking. Treated animals exhibited marked improvements in left ventricular ejection fraction, indicating enhanced cardiac contractility. Histological analyses revealed thicker myocardial walls and reduced scar tissue compared to controls, underscoring the structural benefits of the therapy. Importantly, the formation of functional capillary networks was significantly increased, facilitating improved perfusion and metabolic support for the rehabilitated myocardium.

This integrative strategy also translated into improved survival rates and prolonged cardiac function preservation in the treated cohort. The synergy achieved by addressing multiple pathological targets simultaneously surpasses the outcomes of monotherapy approaches, underscoring the necessity of multifunctional intervention in post-infarction cardiac care. The early timing of therapy post-infarction proved critical, enabling attenuation of maladaptive remodeling cascades before irreversible damage ensued.

Scientifically, this work represents a significant advance in the burgeoning field of regenerative medicine, particularly within the context of mRNA therapeutics. By demonstrating the feasibility and efficacy of delivering multiplexed mRNA payloads via nanomicelles, the study paves the way for future translational research and clinical trials. This platform offers adaptability to incorporate additional or alternative mRNAs tailored to specific injury profiles or patient needs, representing a customizable cardiac repair toolkit.

Considering the global burden of cardiovascular disease and heart failure, the implications of this technology are profound. Beyond myocardial infarctions, similar multipronged mRNA delivery systems may find applications in other ischemic or degenerative cardiac conditions. The potential for mRNA-based regenerative therapies to supplant or complement existing treatments heralds a new era where targeted molecular repair can be achieved with unprecedented precision and efficacy.

As mRNA therapeutics gain momentum in diverse clinical realms, including oncology and infectious diseases, their deployment in cardiology exemplifies the expanding horizons of this versatile modality. The Osaka team’s innovative polyplex nanomicelle delivery system underscores how integrating advanced biomaterials science with molecular biology can overcome longstanding hurdles in tissue regeneration.

In conclusion, the study “Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction” exemplifies a pioneering step toward bespoke regenerative therapies that comprehensively address the multifactorial nature of cardiac injury. By fostering coordinated repair mechanisms through simultaneous multi-mRNA administration, this work charts a promising path to improving outcomes for millions suffering from heart failure worldwide. Future research will be essential to refine dosing strategies, investigate long-term safety, and ultimately translate these findings into human clinical practice.

Subject of Research: Animals

Article Title: Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction

News Publication Date: 23-May-2026

Web References: http://dx.doi.org/10.1002/smsc.20250052

References: DOI: 10.1002/smsc.20250052

Image Credits: 2026, Kazuma Handa et al., Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction, Small Science

Keywords: Cardiology, Heart failure, Heart muscle, Myocardium, Cardiac function, Contractility, Myocardial infarction